Ticker
ACE.ST

Price
8.38
Stock movement down
-0.14 (-1.64%)
Company name
Ascelia Pharma AB (publ)
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Market cap
282.60M
Ent value
126.58M
Price/Sales
-
Price/Book
1.23
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-45.94%
3 year return
-42.05%
5 year return
-
10 year return
-
Last updated: 2024-02-17

DIVIDENDS

ACE.ST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book1.23
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count33.72M
EPS (TTM)-3.35
FCF per share (TTM)-3.83

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-134.00M
Net income (TTM)-112.91M
EPS (TTM)-3.35
EPS (1y forward)-7.20

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash179.81M
Net receivables8.80M
Total current assets196.15M
Goodwill0.00
Intangible assets57.07M
Property, plant and equipment0.00
Total assets254.09M
Accounts payable3.86M
Short/Current long term debt723.00K
Total current liabilities23.56M
Total liabilities23.80M
Shareholder's equity230.29M
Net tangible assets173.22M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-128.79M
Capital expenditures (TTM)167.00K
Free cash flow (TTM)-128.96M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-49.03%
Return on Assets-44.44%
Return on Invested Capital-48.93%
Cash Return on Invested Capital-55.88%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open8.52
Daily high8.57
Daily low8.14
Daily Volume164K
All-time high63.10
1y analyst estimate65.00
Beta0.86
EPS (TTM)-3.35
Dividend per share-
Ex-div date-
Next earnings date16 May 2024

Downside potential

Loading...
Downside potential data
ACE.STS&P500
Current price drop from All-time high-86.72%-0.50%
Highest price drop-95.74%-56.47%
Date of highest drop30 Nov 20239 Mar 2009
Avg drop from high-49.80%-11.40%
Avg time to new high69 days13 days
Max time to new high803 days1805 days
COMPANY DETAILS
ACE.ST (Ascelia Pharma AB (publ)) company logo
Marketcap
282.60M
Marketcap category
Small-cap
Description
Ascelia Pharma AB (publ), a biotech company, engages in the development of oncology-focused orphan drugs in Sweden. The company offers Orviglance (Mangoral), a novel non-gadolinium contrast agent, which is in Phase 3 development for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
Employees
0
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found